Analysts predict that MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) will report sales of $9.00 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for MaxCyte’s earnings, with the lowest sales estimate coming in at $8.90 million and the highest estimate coming in at $9.10 million. MaxCyte reported sales of $7.11 million in the same quarter last year, which indicates a positive year over year growth rate of 26.6%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that MaxCyte will report full-year sales of $43.20 million for the current year. For the next financial year, analysts expect that the firm will report sales of $55.73 million, with estimates ranging from $54.90 million to $57.00 million. Zacks’ sales calculations are an average based on a survey of analysts that cover MaxCyte.
MaxCyte (NASDAQ:MXCT – Get Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. MaxCyte had a negative net margin of 41.15% and a negative return on equity of 7.39%. The firm had revenue of $11.59 million for the quarter, compared to the consensus estimate of $11.00 million.
Shares of NASDAQ MXCT traded up $0.26 during midday trading on Friday, reaching $4.67. 323,517 shares of the company’s stock traded hands, compared to its average volume of 605,307. The stock has a market cap of $474.19 million and a P/E ratio of -27.47. MaxCyte has a one year low of $4.00 and a one year high of $17.44. The stock’s 50 day moving average is $5.61.
MaxCyte Company Profile (Get Rating)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.